Travere Therapeutics (TVTX) Expected to Announce Quarterly Earnings on Wednesday

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) is expected to be releasing its Q2 2025 earnings data after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $100.18 million for the quarter.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.08. Travere Therapeutics had a negative return on equity of 1,179.73% and a negative net margin of 82.88%. The business had revenue of $81.73 million for the quarter, compared to analysts' expectations of $77.44 million. During the same period in the previous year, the firm posted ($1.76) EPS. The business's revenue was up 83.3% on a year-over-year basis. On average, analysts expect Travere Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Travere Therapeutics Stock Up 1.2%

Shares of NASDAQ:TVTX traded up $0.18 during trading on Friday, hitting $15.63. The stock had a trading volume of 764,859 shares, compared to its average volume of 1,636,387. Travere Therapeutics has a 12 month low of $7.93 and a 12 month high of $25.29. The company has a market capitalization of $1.39 billion, a PE ratio of -5.56 and a beta of 0.72. The firm's fifty day moving average is $15.32 and its 200 day moving average is $17.87. The company has a quick ratio of 2.03, a current ratio of 2.05 and a debt-to-equity ratio of 9.46.

Insider Activity at Travere Therapeutics

In other news, CFO Christopher R. Cline sold 1,784 shares of the company's stock in a transaction on Monday, May 5th. The stock was sold at an average price of $21.05, for a total transaction of $37,553.20. Following the transaction, the chief financial officer directly owned 93,126 shares of the company's stock, valued at $1,960,302.30. This represents a 1.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Eric M. Dube sold 18,924 shares of Travere Therapeutics stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $21.05, for a total value of $398,350.20. Following the completion of the sale, the chief executive officer owned 419,173 shares of the company's stock, valued at $8,823,591.65. The trade was a 4.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,294 shares of company stock valued at $485,123 over the last 90 days. Corporate insiders own 4.19% of the company's stock.

Hedge Funds Weigh In On Travere Therapeutics

A hedge fund recently raised its stake in Travere Therapeutics stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 13.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,777 shares of the company's stock after acquiring an additional 6,831 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.06% of Travere Therapeutics worth $1,029,000 as of its most recent filing with the Securities & Exchange Commission.

Wall Street Analysts Forecast Growth

TVTX has been the subject of a number of research reports. Canaccord Genuity Group increased their price objective on Travere Therapeutics from $45.00 to $47.00 and gave the stock a "buy" rating in a report on Thursday, April 10th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Travere Therapeutics in a research note on Wednesday, April 23rd. Stifel Nicolaus lifted their price target on shares of Travere Therapeutics from $22.00 to $23.00 and gave the company a "hold" rating in a research report on Friday, May 2nd. Wedbush reissued an "outperform" rating and set a $30.00 price objective on shares of Travere Therapeutics in a research note on Friday, May 16th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Travere Therapeutics in a research note on Tuesday, July 1st. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $32.14.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.